Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-18
2007-09-18
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S834000, C530S300000, C530S326000
Reexamination Certificate
active
10386777
ABSTRACT:
Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide SEQ ID NO:1 and/or SEQ ID NO:2 and one or more currently used plasminogen activators.
REFERENCES:
patent: 4558010 (1985-12-01), Hung et al.
patent: 6150332 (2000-11-01), Wright et al.
patent: 99/20295 (1999-04-01), None
Zhang et al. Regulation of Single Chain Urokinase Binding, Internalization, and Degradation by a Plasminogen Activator Inhibitor 1-Derived Peptide (1997) J. Biol. Chem. 272(43): 27053-27057.
Simmons M. Cardiol. Clin 1995, 13:339-345, abstract only.
Cipolla M et al., Stroke 2000, 31:940-945.
Higazi, A. A.-R et al., The Journal of Biological Chemistry, 1995, 270:9472-9477.
Wardlaw, J.M. et al., Lancet, 1997, 350:607-614.
Erdem, Y. et al., American Journal of Hypertension, Ltd., 1999, 11:1071-1076.
Adams, David S. et al., The Journal of Biological Chemistry, 1991, 266:8476-8482.
Herz, Joachim, et al., “LRP: a multifunctional scavenger and signaling receptor”, J. Clin. Invest., 2001, 108:779-784.
Haj-Yehia, A. et al., “Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo”, The FASEB Journal, 2000, 14:1411-1422.
Madison, E. L. et al., “Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1”, Proc. Natl. Acad. Sci. USA 87 (1990), 87:3530-3533.
Madison, E. L. et al., “Restoration of Serine Protease-Inhibitor Interaction by Protein Engineering”, The Journal of Biological Chemistry, 1990, 265:21423-21426.
Higazi, A., et al Blood 89: 542-551 (1996).
Higazi A et al J Biol Chem 272: 5348-5353 (1997).
Nashed Nashaat T.
Schnizer Holly
Thrombotech Ltd.
Winston & Strawn LLP
LandOfFree
Peptides for regulation of urokinase (uPA) and tissue type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for regulation of urokinase (uPA) and tissue type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for regulation of urokinase (uPA) and tissue type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3758214